Humira vs Skyrizi
Side-by-side drug price comparison from Medicare Part D data
Verdict
Humira costs 24% less per claim than Skyrizi ($3414.00 vs $4475.00). Humira has a generic alternative available. Total Medicare spending: Humira at $6.5B vs Skyrizi at $2.3B.
| Metric | Humira | Skyrizi |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $3,414* | $4,475 |
| Total Medicare Spending Total Medicare Part D spending on this drug | $6.5B | $2.3B |
| Total Claims | 1,890,000 | 524,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | -22.1%* | 42.8% |
| Generic Available | Yes | No |
| Condition | Autoimmune Diseases | Autoimmune Diseases |
| Total Beneficiaries | 195,000 | 78,000 |
Humira costs 24% less per claim than Skyrizi ($3414.00 vs $4475.00). Humira has a generic alternative available. Total Medicare spending: Humira at $6.5B vs Skyrizi at $2.3B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both Humira and Skyrizi. What follows is the interpretation — which specific axes carry the most weight for Humira versus Skyrizi, and which differences are large enough to influence a real decision.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.